Form 4: HeartBeam Director Nelson Warwick III Reports Changes in Beneficial Ownership

Director Kenneth Warwick Nelson III reports acquisition and disposal of HeartBeam, Inc. securities, including restricted stock units and options.

Summary

• On June 12, 2024, Kenneth Warwick Nelson III, a director of HeartBeam, Inc., reported changes in his beneficial ownership of the company's securities.
• He acquired 33,185 shares of common stock through restricted stock units (RSUs) at a price of $0.
• He also disposed of 127,147 shares.
• Following these transactions, Nelson's holdings include 127,147 shares of common stock.
• He also holds options to buy 70,000 shares of common stock at an exercise price of $2, granted on April 10, 2024.
• The RSUs vest on the earlier of June 12, 2025, or the date of the Issuer's 2025 annual meeting of stockholders, contingent on Nelson remaining an Outside Director.
• The options vest monthly after the commencement date, with full acceleration upon termination following a change in control.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports transactions. The acquisition of RSUs is mildly positive, while the disposal of shares is mildly negative. Overall, it's a factual disclosure.

Positives

• The acquisition of RSUs by a director could be seen as a positive sign of confidence in the company's future.

Negatives

• The disposal of 127,147 shares by the director could be interpreted negatively by investors.

Risks

• The vesting of RSUs is contingent on Nelson remaining an Outside Director, introducing a potential risk if he ceases to hold that position.
• The disposal of shares could indicate a lack of confidence in the company's short-term prospects.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules for RSUs and options provide a timeline for potential future equity ownership changes.

Industry Context

Form 4 filings are standard disclosures for corporate insiders and provide transparency into their transactions in the company's securities. This filing is specific to HeartBeam, Inc. and its director.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency of insider transactions.
• Companies like HeartBeam, in the medical technology sector, are often scrutinized for insider activity as it can reflect confidence in the company's technology and market prospects.
• Comparable companies would also have similar filings when their directors or officers trade company stock.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The vesting of RSUs and options could impact future equity dilution.

Key Dates